TNF-related Apoptosis-inducing Ligand in Cardiovascular Disease: Insights from Hypertensive Urgencies and Acute Heart Failure

Khayungali Le^*
*Correspondence: Khayungali Le, Department of Internal Medicine, Guangxi Medical University, Nanning 530021, China, Email:

Introduction

Cardiovascular Diseases (CVD) remain a leading cause of morbidity and mortality worldwide, encompassing a spectrum of conditions from hypertensive urgencies to Acute Heart Failure (AHF). Within this complex landscape, emerging biomarkers and molecular pathways such as Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) have garnered attention for their potential roles in disease pathogenesis and clinical outcomes [1]. TRAIL, originally identified for its apoptosis-inducing effects in cancer cells, is now recognized for its diverse functions in cardiovascular health and disease. Hypertensive urgencies, characterized by severely elevated blood pressure without acute end-organ damage and AHF, marked by sudden exacerbation of heart failure symptoms, represent critical junctures in the cardiovascular continuum where TRAIL's involvement is increasingly elucidated. Beyond its role in apoptosis, TRAIL influences vascular endothelial function, inflammation and immune responses, thereby impacting vascular integrity and cardiac function. Understanding TRAIL's intricate mechanisms and clinical implications in these contexts provides insights into novel diagnostic strategies, prognostic markers and therapeutic targets aimed at mitigating cardiovascular risk and improving patient outcomes. This paper explores the multifaceted role of TRAIL in cardiovascular disease, with a focus on its mechanisms of action, clinical implications in hypertensive urgencies and AHF, biomarker potential, therapeutic implications, recent research advances and translational insights. By delving into TRAIL's contributions to vascular biology and cardiac pathology, we aim to underscore its relevance in contemporary cardiovascular medicine and pave the way for future research endeavors aimed at harnessing its therapeutic potential [2].

Description

Mechanisms of TRAIL in cardiovascular disease: TRAIL functions through Death Receptors (DR4 and DR5) and Decoy Receptors (DcR1 and DcR2) to induce apoptosis in cancer cells. In cardiovascular disease, TRAIL's effects extend beyond apoptosis to include modulation of vascular endothelial function, inflammation and immune responses. TRAIL has been implicated in endothelial cell survival, angiogenesis and vascular homeostasis, suggesting a dual role in both cardiovascular protection and pathogenesis depending on the context and disease state [3].

TRAIL and hypertensive urgencies: Hypertensive urgencies represent a clinical scenario where severe hypertension (>180/120 mmHg) occurs without acute end-organ damage. The rapid increase in blood pressure can trigger endothelial dysfunction, oxidative stress and inflammation, contributing to vascular damage and cardiovascular events. Recent studies have explored the association between TRAIL levels and endothelial dysfunction in hypertensive urgencies, highlighting its potential as a biomarker of vascular injury and predictor of adverse cardiovascular outcomes.

TRAIL in acute heart failure: Acute Heart Failure (AHF) encompasses a spectrum of clinical presentations characterized by sudden onset or exacerbation of symptoms due to cardiac dysfunction. The pathophysiology of AHF involves neurohormonal activation, myocardial ischemia and inflammatory responses, all of which influence disease progression and outcomes. TRAIL's role in AHF revolves around its impact on cardiac remodeling, apoptosis of cardiomyocytes and modulation of inflammatory pathways implicated in myocardial injury and dysfunction [4].

Clinical implications and biomarker potential: Assessing TRAIL levels in hypertensive urgencies and AHF may provide insights into disease severity, prognosis and response to therapy. Elevated TRAIL levels have been associated with increased cardiovascular risk and adverse outcomes in various cardiovascular conditions, suggesting its potential utility as a prognostic biomarker. Integrating TRAIL measurement into clinical practice could enhance risk stratification and guide personalized treatment approaches tailored to individual cardiovascular risk profiles.

Therapeutic implications and future directions: Targeting TRAIL signaling pathways presents novel therapeutic opportunities in cardiovascular disease management. Strategies aimed at modulating TRAIL expression or activity, such as TRAIL receptor agonists or antagonists, hold promise for attenuating vascular damage, promoting endothelial repair and improving cardiac function in hypertensive urgencies and AHF. Future research efforts should focus on elucidating TRAIL's specific roles in different cardiovascular contexts, refining biomarker utility and translating experimental findings into clinical applications [5].

Research advances and translational insights: Recent advancements in TRAIL research have expanded our understanding of its pleiotropic effects in cardiovascular disease, moving beyond its traditional role in apoptosis to encompass broader implications for vascular health and cardiac function. Translational studies linking basic science discoveries with clinical outcomes are essential for bridging the gap between bench and bedside, ultimately improving diagnostic precision, therapeutic efficacy and patient outcomes in cardiovascular medicine.

Conclusion

In conclusion, Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) represents a multifaceted player in cardiovascular disease, offering insights into pathophysiological mechanisms, clinical implications and therapeutic opportunities in hypertensive urgencies and acute heart failure. Its involvement in vascular endothelial function, inflammation and cardiac remodeling underscores its potential as a biomarker and therapeutic target for mitigating cardiovascular morbidity and mortality. As research continues to unravel TRAIL's intricate roles in different cardiovascular contexts, integrating TRAIL assessment into clinical practice holds promise for enhancing risk stratification, optimizing treatment strategies and improving cardiovascular outcomes. Future studies should focus on validating TRAIL as a biomarker, exploring targeted therapies and advancing personalized approaches to cardiovascular disease management based on TRAIL-mediated pathways.

Acknowledgment

None.

Conflict of Interest

No conflict of interest.

References

1. Groenewegen, Amy, Frans H. Rutten, Arend Mosterd and Arno W. Hoes. "Epidemiology of heart failure." Eur J Heart Fail 22 (2020): 1342-1356.

Google Scholar, Crossref, Indexed at

2. Liberale, Luca, Fabrizio Montecucco, Jean-Claude Tardif and Peter Libby, et al. "Inflamm-ageing: The role of inflammation in age-dependent cardiovascular disease." Eur Heart J 41 (2020): 2974-2982.

Google Scholar, Crossref, Indexed at

3. Dhingra, Ravi and Ramachandran S. Vasan. "Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers." Trends Cardiovas Med 27 (2017): 123-133.

Google Scholar, Crossref, Indexed at

4. Schiffrin, Ernesto L. "Vascular remodeling in hypertension: Mechanisms and treatment." Hypertension 59 (2012): 367-374.

Google Scholar, Crossref, Indexed at

5. Fortuño, Maria Antonia, Susana Ravassa, Ana Fortuño and Guillermo Zalba, et al. "Cardiomyocyte apoptotic cell death in arterial hypertension: Mechanisms and potential management." Hypertension 38 (2001): 1406-1412.

Google Scholar, Crossref, Indexed at